National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovation ...

Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis ...

Operator: Good morning, and welcome to Alico's Third Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, today's call is being recorded. I would now like to turn the call over to your ...

The reason to be bullish for this program, which I'm going to go over in detail below, is because it was able to initiate a rolling New Drug Application [NDA] of ALXN1840 for the treatment of these ...

Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference ...

Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - ...

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinica ...

On 9 February 2026, the chief executive of pan-African telecoms operator Paratus Group announced the activation of the terrestrial fibre backbone G2M (Goma-to-Mombasa), a 2,000 km route directly ...

Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designationNDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurol ...

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Record Q2 Revenue, EAI Robotics Entering a Phase ...

OPENEDGES specializes in high-performance memory subsystem IP design suitable for many on-device AI chip development.

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 205,334 IPC common shares (ISIN: CA46016U1084) during ...